Navigation Links
Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
Date:3/14/2011

TOKYO, March 14, 2011 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the European Commission (EC) has granted marketing authorization for Teysuno™ (S-1), a novel oral anti-cancer agent indicated for the treatment of adults with advanced gastric cancer when given in combination with cisplatin. The authorization is applicable to the 27 Member States and the three European Economic Area (EEA) countries of the European Union (EU).

"For European patients living with gastric cancer, the availability of this new treatment option is a timely addition to the therapeutic landscape," said Alfredo Carrato, MD, Professor and Director of the Medical Oncology Department at Ramon y Cajal University Hospital in Madrid, Spain.

A member of the fluoropyrimidine class of anticancer agents, Teysuno™ is a combination of three pharmacological compounds. The main active substance in Teysuno, tegafur, is a prodrug of a chemical called 5-fluorouracil (5-FU), meaning that it is converted in the body to 5-FU. In the body, 5-FU interferes with the enzymes involved in making DNA. As a result, it can prevent the growth of cancer cells or result in cell death.

The two other active substances in Teysuno™ allow tegafur to be effective at lower doses and with fewer side effects. Specifically, gimeracil prevents the breakdown of 5-FU and oteracil reduces the activity of 5-FU in normal, non-cancerous tissue in the gut.

The EC's marketing authorization decision was based in part on the results of the First-Line Advanced Gastric Cancer Study (FLAGS), the largest international Phase III trial ever conducted in patients with advanced gastric cancer.

"We are pleased that the European Commission has recognized the importance of the FLAGS study findings, which showed that Teysuno-based combination therapy was as effective as a comparator regimen, with an acceptable safety profile,
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
2. ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment of Stargardts Disease
3. Mylans Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg
4. Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
5. EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
6. Rensselaer professor Daniel Lewis receives NSF CAREER Award
7. Pacific Shore Holdings, Inc. Receives Symbol Change Approval From FINRA
8. Boston College receives W.M. Keck Foundation funding for nanoscale optical microscope
9. CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices
10. Dr. Stefan Strauf of physics at Stevens receives NSF CAREER Award for quantum research
11. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
(Date:7/24/2014)... Brook, NJ (PRWEB) July 24, 2014 ... to manage numerous projects in the MENA region during ... to have a preferred provider agreement with DZS to ... the MENA region,” said Global VP of R&D and ... "DZS has developed excellent operational practices with a focus ...
(Date:7/23/2014)... , July 24, 2014 Lyfebulb, ... Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North ... or "the Company"), announced a collaboration to increase ... last night at an event attended by more ... parties. Lyfebulb is a health and wellness company ...
(Date:7/23/2014)... Inc. (NASDAQ: SGMO ) today reported its ... For the second quarter ended June 30, 2014, ... or $0.10 per share, compared to a net loss ... same period in 2013. As of June 30, 2014, ... interest receivable of $236.7 million. Revenues for ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9
... 2011 Reportlinker.com announces that a new market ... Global Biotechnology Reagents Industry ... report analyzes the worldwide markets for Biotechnology Reagents ... Cell/Tissue Culture Reagents, DNA Sequencing/Synthesis Reagents, Electrophoresis Reagents, ...
... Feb. 23, 2011 Ingenuity® Systems, a leading ... science researchers, today announced a research collaboration with ... sequencing (NGS) data analysis. Covance Genomics Laboratory, a ... discovery and development industry, and Ingenuity will work ...
... State University have developed a faster, easier way ... by using liquid metal. Microfluidic devices manipulate small ... of applications, from testing minute blood samples to ... easier to incorporate electrodes into microfluidic devices, we ...
Cached Biology Technology:Reportlinker Adds Global Biotechnology Reagents Industry 2Ingenuity Systems and Covance Collaborate to Support Next-Generation Sequencing Research 2Liquid metal key to simpler creation of electrodes for microfluidic devices 2
(Date:7/24/2014)... Forest is a hotspot of biodiversity and one of ... and toads) in the world. However, current levels of ... years has been an increase in the description of ... advance of molecular techniques and availability of samples for ... of samples for molecular and morphological analysis, researchers from ...
(Date:7/24/2014)... Neiker-Tecnalia is currently conducting research into the potato genes ... characterised by a reduction in rainfall and increased extremes ... the most resistant genes in order to create new ... conditions.The research is also seeking to find out how ... of greater drought and higher and lower temperatures. , ...
(Date:7/24/2014)... German . ... sufferers worldwide, a further 600 million people living with ... population contending with allergic rhinitis (allergic inflammation of the ... organs and parts of the body beyond the respiratory ... form of inflammatory bowel diseases such as colitis ulcerosa), ...
Breaking Biology News(10 mins):A tiny new species of frog from Brazil with a heroic name 2Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3
... of Genes & Development, Dr. Karlene Cimprich and colleagues ... sufficient to activate the ATR-mediated DNA damage checkpoint. ... Dr. Cimprich. "The ability to precisely define and manipulate ... experimental system will enable us to control, quantitative and ...
... to preserve grapes could help prevent allergies and boost healthy ... & Industry, the magazine of the SCI. The same technique ... wines without the added sulphites that can cause asthma and ... remain in storage for months and are usually treated with ...
... knowledge of the properties and actions of enzymes, scientists have ... originally isolated from blue-green algae. , This accomplishment is ... promising drugs for use in clinical trials. , In ... of the journal ACS Chemical Biology, a scientific team lead ...
Cached Biology News:Grape expectations for healthier wine 2Turning green gunk to gold, anti-cancer gold 2
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
96 Well Plate EB, RE bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes. Guaranteed coefficient of variation (CVs)....
... shakers combine high durability and capacity with ... heavy-duty mechanism prevents vibration, allowing the unit ... Every other part, from the large rubber ... machined aluminum platform is designed to last ...
...
Biology Products: